ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The allele ɛ4 of apolipoprotein E (apoE4) is the most prevalent genetic risk factor for Alzheimer's disease (AD) and is therefore a promising therapeutic target. Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Aβ42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits. Since the RXR system has numerous other targets, it is important to devise the means of activating ABCA1 selectively. We presently utilized CS-6253, a peptide shown to directly activate ABCA1 in vitro, and examined the extent to which it can affect the degree of lipidation of apoE4 in vivo and counteract the associated brain and behavioral pathologies. This revealed that treatment of young apoE4-targeted replacement mice with CS-6253 increases the lipidation of apoE4. This was associated with a reversal of the apoE4-driven Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as of the synaptic impairments and cognitive deficits. These findings suggest that the pathological effects of apoE4 in vivo are associated with decreased activation of ABCA1 and impaired lipidation of apoE4 and that the downstream brain-related pathology and cognitive…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“peptide mimetics used to upregulate ABCA1 were shown to increase APOE4 lipidation and reduce Aβ deposition and cognitive deficits in APOE4 knock-in (but not APOE3 knock-in) plaque-depositing mice, indicating that directly targeting APOE lipidation is an effective therapeutic approach212”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [212]
In the citing paper
“indicating that directly targeting APOE lipidation is an effective therapeutic approach212”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [212]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“Genetic studies of sporadic Alzheimer’s disease (AD) and of families with late onset AD revealed that the allele APOE (cid:2) 4 (apoE4) is a genetic risk factor for AD [1–3].”
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347 · cited 1×
“transcription regulating system [18–20].”
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · cited 1×
“:+9723 6409624;Fax:+97236406356;E-mail:dmichael@post.tau.ac.il. allele, which renders it the most prevalent genetic risk factor for AD [2].”
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693 · cited 1×
“…CS-6253 accumulates in the brain and co-localizes with astrocytes, which are enriched with ABCA1 and are the major source of brain apoE [15, 38, 39] was assessed immunohistochemically by double staining of the hippocampus utilizing the anti-CS-6253 Ab and an Ab directed at the astrocytic…”
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
Alzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · cited 1×
“[24].”
Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., & Roses, A. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11183 · Cited by 474
Research works printed but not linked: 1
- Salomon-Zimri, 2015, Behavioral testing affects the phenotypic expression of APOE ɛ3 and APOE ɛ4 in targeted replacement mice and reduces the differences between them, Alzheimers Dement (Amst), 1, 127, 10.1016/j.dadm.2014.11.014 · DOI
Cited by
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“Peptide mimetics used to upregulate ABCA1 have been shown to increase apoE4 lipidation, and reduce Aβ, tau, and cognitive deficits in a mouse model [207].”
BackgroundApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Self-citationYin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease
Marais, A. D. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.002 · Cited by 382
APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics
Husain, M. A., Laurent, B., & Plourde, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.630502 · Cited by 353
“Intraperitoneal injection of CS-6253 injection, an ABCA1 agonist peptide, increased apoE4 lipidation, decreased Aβ accumulation and tau hyperphosphorylation as well as reduced cognitive deficits in APOE4-TR mice (Boehm-Cagan et al., 2016).”
BackgroundApolipoprotein E in lipid metabolism and neurodegenerative disease
Yang, L. G., March, Z. M., Stephenson, R. A., & Narayan, P. S. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.05.002 · Cited by 286
Itoh, N., Itoh, Y., Tassoni, A., Ren, E., Kaito, M., Ohno, A., Ao, Y., Farkhondeh, V., Johnsonbaugh, H., Burda, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716032115 · Cited by 253
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
“…peptide mimetics used to upregulate ABCA1 were shown to increase APOE4 lipidation and reduce Aβ deposition and cognitive deficits in APOE 4 knock-in (but not APOE 3 knock-in) plaque-depositing mice, indicating that directly targeting APOE lipidation is an effective therapeutic approach 212 (Fig.”
ApoE Lipidation as a therapeutic target in Alzheimer’s disease
Lanfranco, M. F., Ng, C. A., & Rebeck, G. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176336 · Cited by 189
Moulton, M. J., Barish, S., Ralhan, I., Chang, J., Goodman, L. D., Harland, J. G., Marcogliese, P. C., Johansson, J. O., Ioannou, M. S., & Bellen, H. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112095118 · Cited by 180
Self-citationApolipoprotein E and Alzheimer's disease
Troutwine, B. R., Hamid, L., Lysaker, C. R., Strope, T. A., & Wilkins, H. M. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.002 · Cited by 156
Astrocyte-oligodendrocyte interaction regulates central nervous system regeneration
Molina-Gonzalez, I., Holloway, R. K., Jiwaji, Z., Dando, O., Kent, S. A., Emelianova, K., Lloyd, A. F., Forbes, L. H., Mahmood, A., Skripuletz, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39046-8 · Cited by 176
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D. R., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 171
The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease
Jacobo-Albavera, L., Domínguez-Pérez, M., Medina-Leyte, D. J., González-Garrido, A., & Villarreal-Molina, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041593 · Cited by 159
Intracellular Cholesterol Trafficking and Impact in Neurodegeneration
Arenas, F., Garcia-Ruiz, C., & Fernandez-Checa, J. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00382 · Cited by 158
ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes
Rawat, V., Wang, S., Sima, J., Bar, R., Liraz, O., Gundimeda, U., Parekh, T., Chan, J., Johansson, J. O., Tang, C., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1400-19.2019 · Cited by 165
“This may provide an explanation for the previously observed neuroprotective effects of CS-6253 in vivo: decreased intraneuronal A and tau, improved synaptic markers and cognitive deficits in ApoE4-TR mice (Boehm-Cagan et al., 2016).”
BackgroundMethodSelf-citationThe role of APOE on lipid homeostasis and inflammation in normal brains
Rebeck, G. W. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075408 · Cited by 160
“smaller complexes in normal mouse brains (34, 35), and”
BackgroundPires, M., & Rego, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010778 · Cited by 157
Cellular cholesterol homeostasis and Alzheimer’s disease
Chang, T.-Y., Yamauchi, Y., Hasan, M. T., & Chang, C. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075630 · Cited by 155
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Flowers, S. A., & Rebeck, G. W. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104724 · Cited by 149
Grimm, M. O. W., Michaelson, D. M., & Hartmann, T. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076331 · Cited by 109
Self-citationReelin: Neurodevelopmental Architect and Homeostatic Regulator of Excitatory Synapses
Wasser, C. R., & Herz, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.766782 · Cited by 111
ABC transporters: human disease and pharmacotherapeutic potential
Moore, J. M., Bell, E. L., Hughes, R. O., & Garfield, A. S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.11.001 · Cited by 101
Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities
Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91
“Other compounds tested include the RXR agonists: LG100268, T0901317, GW3965 or ABCA1 agonists such as CS-6253, which showed benefits in cell and animal models of AD [215– 218].”
DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA
Yassine, H. N., Croteau, E., Rawat, V., Hibbeln, J. R., Rapoport, S. I., Cunnane, S. C., & Umhau, J. C. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0250-1 · Cited by 71
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Fernandez, H. R., Varma, A., Flowers, S. A., & Rebeck, G. W. (2020) · Cancers · doi:10.3390/cancers12123842 · Cited by 58
Chernick, D., Ortiz-Valle, S., Jeong, A., Qu, W., & Li, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134306 · Cited by 62
He, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease
Bossaerts, L., Cacace, R., & Broeckhoven, C. V. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00536-w · Cited by 58
Chen, Y., Jin, H., Chen, J., Li, J., Găman, M., & Zou, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02600-y · Cited by 64
Wang, S., Li, B., Li, J., Cai, Z., Hugo, C., Sun, Y., Qian, L., TCW, J., Chui, H. C., Dikeman, D., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00802-7 · Cited by 39
Chernick, D., Ortiz‐Valle, S., Jeong, A., Swaminathan, S. K., Kandimalla, K. K., Rebeck, G. W., & Li, L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14554 · Cited by 51
Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway
Fan, J., Zhao, R. Q., Parro, C., Zhao, W., Chou, H.-Y., Robert, J., Deeb, T. Z., Raynoschek, C., Barichievy, S., Engkvist, O., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081851 · Cited by 50
Jia, Y., Wang, N., Zhang, Y., Xue, D., Lou, H., & Liu, X. (2020) · Aging and disease · doi:10.14336/ad.2019.0519 · Cited by 46
Yue, Q., Leng, X., Xie, N., Zhang, Z., Yang, D., & Hoi, M. P. M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70079 · Cited by 48
Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
Campos‐Peña, V., Pichardo-Rojas, P. S., Sánchez-Barbosa, T., Ortíz-Islas, E., Rodríguez-Pérez, C. E., Montes, P., Ramos-Palacios, G., Silva‐Adaya, D., Quintana, R. V., Cerna-Cortés, J. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012092 · Cited by 47
Emerging Role of ABC Transporters in Glia Cells in Health and Diseases of the Central Nervous System
Villa, M., Wu, J., Hansen, S. M., & Pahnke, J. (2024) · Cells · doi:10.3390/cells13090740 · Cited by 44
Targeting Apolipoprotein E for Alzheimer’s Disease: An Industry Perspective
Suidan, G. L., & Ramaswamy, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092161 · Cited by 42
“reversed Aβ42 depositi a d tau hyperphosphorylation in apoE4-tar ted repl cement mice [53],”
BackgroundInfluentialMitochondrial Cholesterol in Alzheimer's Disease and Niemann–Pick Type C Disease
Torres, S., García‐Ruiz, C., & Fernández-Checa, J. C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01168 · Cited by 45
The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease
Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 44
Valkenburgh, J. S. V., Meuret, C. J., Martinez, A. E., Kodancha, V., Solomon, V. A., Chen, K., & Yassine, H. N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.700847 · Cited by 41
Wan, T., Fu, M., Jiang, Y., Jiang, W., Li, P., & Zhou, S. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03448-1 · Cited by 40
Kloske, C. M., Dugan, A. J., Weekman, E. M., Winder, Z., Patel, E., Nelson, P. T., Fardo, D. W., & Wilcock, D. M. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab085 · Cited by 38
Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease
Miziak, B., Błaszczyk, B., & Czuczwar, S. J. (2021) · Pharmaceuticals · doi:10.3390/ph14050458 · Cited by 37
The Interplay Between Apolipoprotein E4 and the Autophagic–Endocytic–Lysosomal Axis
Schmukler, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0892-4 · Cited by 35
Self-citationThe role of the ATP-Binding Cassette A1 (ABCA1) in neurological disorders: a mechanistic review
Paseban, T., Alavi, M. S., Etemad, L., & Roohbakhsh, A. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2235718 · Cited by 34
Puris, E., Auriola, S. O. K., Petralla, S., Hartman, R., Gynther, M., de Lange, E. C. M., & Fricker, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105741 · Cited by 31
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
Noveir, S. D., Kerman, B. E., Xian, H., Meuret, C. J., Smadi, S., Martinez, A. E., Johansson, J., Zetterberg, H., Parks, B. A., Kuklenyik, Z., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01028-1 · Cited by 30
Self-citationDifferential effects of apoE4 and activation of ABCA1 on brain and plasma lipoproteins
Boehm-Cagan, A., Bar, R., Harats, D., Shaish, A., Levkovitz, H., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166195 · Cited by 29
Self-citationChen, J., Zhao, S., Zhou, Y., Wang, L., Chen, Q., & Zheng, K. (2025) · BioScience Trends · doi:10.5582/bst.2025.01148 · Cited by 33
Pahnke, J., Bascuñana, P., Brackhan, M., Stefan, K., Namasivayam, V., Koldamova, R. P., Wu, J., Möhle, L., & Stefan, S. M. (2021) · Free Neuropathology · doi:10.17879/freeneuropathology-2021-3528 · Cited by 36
Central and Peripheral Mechanisms in ApoE4-Driven Diabetic Pathology
Koren-Iton, A., Salomon‐Zimri, S., Smolar, A., Stein, E. S., Dori, A., Chapman, J., & Michaelson, D. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041289 · Cited by 28
Self-citationAstrocytic transporters in Alzheimer's disease
Ugbode, C., Hu, Y., Whalley, B., Peers, C., Rattray, M., & Dallas, M. L. (2017) · Biochemical Journal · doi:10.1042/bcj20160505 · Cited by 25
Protective Variants in Alzheimer’s Disease
Andrews, S. J., Fulton‐Howard, B., & Goate, A. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-0156-2 · Cited by 28
APOE4 expression is associated with impaired autophagy and mitophagy in astrocytes
Pinkas‐Kramarski, R., & Schmukler, E. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.322452 · Cited by 25
Asante, I., Louie, S. G., & Yassine, H. N. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14907 · Cited by 26
Valencia-Olvera, A. C., Balu, D., Faulk, N., Amiridis, A., Wang, Y., Pham, C., Avila-Munoz, E., York, J. M., Thatcher, G. R. J., & LaDu, M. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01375-3 · Cited by 22
“%) for 1 h and incubated overnight with primary antibodies against PSD95, drebrin, β-actin, β-tubulin, ABCA1, APP, and C-terminal fragments (CTF) at 4 °C.”
InfluentialЛю, Ч., Liu, J., Wang, Y., Xu, S.-F., & Yu, L.-M. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05629-3 · Cited by 25
APOE-Targeted Therapeutics for Alzheimer's Disease
Yassine, H. N., Hugo, C., O'Donovan, B., Stephens, I. O., Johnson, L. A., Cole, G., TCW, J., Johansson, J., Kisler, K., & Chiba-Falek, O. (2025) · The Journal of Neuroscience · doi:10.1523/jneurosci.1388-25.2025 · Cited by 20
Self-citationHu, H., Wan, S., Hu, Y., Wang, Q., Li, H., & Zhang, N. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2445194 · Cited by 21
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20
Zhang, W.-X., Yang, Y.-L., Yu, J., Jia, L., & Huang, H. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152335 · Cited by 20
Ficulle, E., Kananathan, S., Airey, D., Gharbi, S., Humphryes-Kirilov, N., Scherschel, J., Dunbar, C., Eastwood, B. J., Laing, E., Collier, D. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06411-4 · Cited by 18
Cerasuolo, M., Papa, M., Colangelo, A. M., & Rizzo, M. R. (2023) · Biomedicines · doi:10.3390/biomedicines11030861 · Cited by 18
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01353-z · Cited by 19
Self-citationRahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
ApoE: The Non-Protagonist Actor in Neurological Diseases
Grimaldi, L., Bovi, E., Formisano, R., & Sancesario, G. M. (2024) · Genes · doi:10.3390/genes15111397 · Cited by 18
Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia
Lee, J. Y., Marian, O. C., & Don, A. S. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08644-4 · Cited by 20
DNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously
Smith, M. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00024 · Cited by 20
The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo
Salomon‐Zimri, S., Koren-Iton, A., Angel, A., Ben‐Zur, T., Offen, D., & Michaelson, D. M. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190228120254 · Cited by 18
Self-citationYu, S., Qian, L., & Ma, J. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026141 · Cited by 15
Cognitive deficits in human ApoE4 knock-in mice: A systematic review and meta-analysis
van Heuvelen, M. J. G., van der Lei, M. B., Alferink, P. M., Roemers, P., & van der Zee, E. A. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115123 · Cited by 16
Bar, R., Boehm‐Cagan, A., Luz, I., Kleper‐Wall, Y., & Michaelson, D. M. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.08.003 · Cited by 13
Self-citationTargeting lipid metabolism in neurodegenerative diseases: From experimental to clinical
Long, J., Liu, S., Shi, Y., Zhang, C., Li, Q., & Ai, Q. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156436 · Cited by 15
Research Progress of Lipid Metabolism-Mediated Neuroinflammation in Alzheimer’s Disease
Shen, Y., Wang, X., Liu, X., Wang, G., Hou, X., & Zhou, X. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01648-9 · Cited by 12
Chaves, J. C. S., Wasielewska, J. M., Cuní‐López, C., Rantanen, L. M., Lee, S., Koıstınaho, J., White, A. R., & Oikari, L. E. (2023) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.009 · Cited by 11
Zhu, M., Jia, L., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210411 · Cited by 9
Safieh, M., Liraz, O., Ovadia, M., & Michaelson, D. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230514 · Cited by 9
Self-citationHuo, C., Chen, M., Hour, T., Huang, L., Fong, Y.-O., Kuo, Y., Yang, Y., & Chuu, C. (2022) · Brain Sciences · doi:10.3390/brainsci12091134 · Cited by 9
Unraveling APOE4: The dual role in CNS and peripheral inflammation in Alzheimer's disease
Li, X., Li, Z., Chen, H., Guo, H., Ge, Y., Dong, F., Zhang, F., & Zhang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115199 · Cited by 8
Unni, P. A., Pillai, G. G., & Sajithalulu, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119079 · Cited by 8
Detoxification and age-related neurodegenerative diseases: Correlation and therapeutic potential
Yan, Y., Maisenbacher, M., Huang, C., & Fan, S. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107849 · Cited by 6
Apolipoprotein-mimetic Peptides: Current and Future Prospectives
Pande, A. H., Nankar, S. A., Ahmed, S., & Sharma, S. S. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666221003122624 · Cited by 7
Qian, L., Wang, G., Li, B., Su, H., & Qin, L. (2024) · PeerJ · doi:10.7717/peerj.16740 · Cited by 6
Patil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 8
Alzheimer’s Disease Pharmacology
Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 8
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 6
Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer’s disease
Marian, O. C., Tran, C., & Don, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00023-3 · Cited by 5
Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
Patel, K., Srivastava, S., Kushwah, S., & Mani, A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210027 · Cited by 4
Chintapalli, R., Mowforth, O. D., & Davies, B. M. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111247 · Cited by 3
Ugolotti, M., Papotti, B., Trentini, A., Mola, G., Cervellati, C., Adorni, M. P., & Zimetti, F. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128411158250909151734 · Cited by 3
ABCA1: A Therapeutic Target for Improving Cholesterol Homeostasis in Peripheral Neuropathies
Woo, Y. H., Schmidt, N. E., Johansson, J. O., & Notterpek, L. M. (2026) · Biomolecules · doi:10.3390/biom16020332 · Cited by 2
Self-citationRamírez, U. A. T., Medina, M. E., Ruiz, A. P. R., Borja, M. D. L. Á. S., & Ricoy, O. U. D. (2021) · Lux Médica · doi:10.33064/48lm20212964 · Cited by 1
Nawabi, A. Q., Yang, M., Cai, X., Gou, W., Hou, J., Nizami, V., & Dai, Q. (2019) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2019.911074 · Cited by 2
Metadata
- Authors
- Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M.
- Affiliations
- The Department of Neurobiology, The George S. Wise Faculty of Life Sciences, The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Tel Aviv University (IL)
- Lawrence Berkeley National Laboratory (US)
- Artery Therapeutics, Inc., San Ramon, CA, USA
- Corresponding author
- Michaelson, Daniel M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-10-04
- Volume
- 54
- Issue
- 3
- Pages
- 1219-1233
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2516112233
- Cited by
- 116
- References
- 52
- Citations by year
- 2026: 2 · 2025: 17 · 2024: 19 · 2023: 11 · 2022: 15 · 2021: 16 · 2020: 11 · 2019: 8 · 2018: 4 · 2017: 11 · 2016: 2
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ABCA1, APOE ε4
- MeSH terms
- Animals, Brain, Cognition Disorders, Male, Mice, Inbred C57BL, Mice, Transgenic, Peptides, Mice, Apolipoprotein E4, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.